According to the Complaint, Akebia is a biopharmaceutical company that focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor ("HIF") biology for patients with kidney disease. Akebia's lead product candidate is AKB-6548, an oral therapy which has completed a Phase 2b study for the treatment of anemia related to chronic kidney disease ("CKD") in non-dialysis patients, as well as tested in a Phase 2 study for the treatment of anemia in patients undergoing dialysis.
The Complaint alleges Defendants negligently issued untrue statements of material facts and omitted to state material facts required to he stated from the Registration Statement and incorporated Offering Materials that the Company filed with the SEC in support of the Company's March 20, 2014 initial Public Offering.
On April 29, 2016, the Court issued an Order allowing the plaintiff's Motion to Remand. This case was remanded to the Suffolk County Superior Court of the Commonwealth of Massachusetts.
Company & Securities Information
Defendant: Akebia Therapeutics, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: AKBA
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Anthony Fortunato, et al. v. Akebia Therapeutics, Inc., et al.